<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">
<pmc-articleset><article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="case-report">
  <?properties open_access?>
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">An Bras Dermatol</journal-id>
      <journal-id journal-id-type="iso-abbrev">An Bras Dermatol</journal-id>
      <journal-id journal-id-type="publisher-id">abd</journal-id>
      <journal-title-group>
        <journal-title>Anais Brasileiros de Dermatologia</journal-title>
      </journal-title-group>
      <issn pub-type="ppub">0365-0596</issn>
      <issn pub-type="epub">1806-4841</issn>
      <publisher>
        <publisher-name>Sociedade Brasileira de Dermatologia</publisher-name>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="pmid">27828640</article-id>
      <article-id pub-id-type="pmc">5087225</article-id>
      <article-id pub-id-type="doi">10.1590/abd1806-4841.20164322</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Case Report</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Alemtuzumab in refractory S&#xE9;zary syndrome<xref ref-type="fn" rid="fn1">*</xref></article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name>
            <surname>Reifs</surname>
            <given-names>Carmen Mar&#xED;a Alc&#xE1;ntara</given-names>
          </name>
          <xref ref-type="aff" rid="aff1">1</xref>
          <xref ref-type="corresp" rid="c1"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Salido-Vallejo</surname>
            <given-names>Rafael</given-names>
          </name>
          <xref ref-type="aff" rid="aff1">1</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Garnacho-Saucedo</surname>
            <given-names>Gloria Mar&#xED;a</given-names>
          </name>
          <xref ref-type="aff" rid="aff1">1</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>la Corte-S&#xE1;nchez</surname>
            <given-names>Sof&#xED;a De</given-names>
          </name>
          <xref ref-type="aff" rid="aff1">1</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Gonz&#xE1;lez-Menchen</surname>
            <given-names>Alberto</given-names>
          </name>
          <xref ref-type="aff" rid="aff1">1</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Garc&#xED;a-Nieto</surname>
            <given-names>Antonio V&#xE9;lez</given-names>
          </name>
          <xref ref-type="aff" rid="aff1">1</xref>
        </contrib>
        <aff id="aff1"><label>1</label>Hospital Universitario Reina Sof&#xED;a &#x2013;
C&#xF3;rdoba, Spain</aff>
      </contrib-group>
      <author-notes>
        <corresp id="c1">Mailing address: Carmen Mar&#xED;a Alc&#xE1;ntara Reifs,
Avenida Men&#xE9;ndez Pidal s/n, 14004 C&#xF3;rdoba, Spain. E-mail:
<email>ayla88_@hotmail.com</email></corresp>
      </author-notes>
      <pub-date pub-type="epub-ppub">
        <season>Sep-Oct</season>
        <year>2016</year>
      </pub-date>
      <!--Fake ppub date generated by PMC from publisher
							pub-date/@pub-type='epub-ppub' -->
      <pub-date pub-type="ppub">
        <season>Sep-Oct</season>
        <year>2016</year>
      </pub-date>
      <volume>91</volume>
      <issue>5</issue>
      <fpage>642</fpage>
      <lpage>644</lpage>
      <history>
        <date date-type="received">
          <day>22</day>
          <month>12</month>
          <year>2014</year>
        </date>
        <date date-type="accepted">
          <day>10</day>
          <month>2</month>
          <year>2015</year>
        </date>
      </history>
      <permissions>
        <copyright-statement>&#xA9;2016 by Anais Brasileiros de
Dermatologia</copyright-statement>
        <copyright-year>2016</copyright-year>
        <copyright-holder>Anais Brasileiros de Dermatologia</copyright-holder>
        <license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by-nc/4.0/">
          <license-p>This is an Open Access article distributed under the terms of the
Creative Commons Attribution Non-Commercial License which permits
unrestricted non-commercial use, distribution, and reproduction in any
medium provided the original work is properly cited.</license-p>
        </license>
      </permissions>
      <abstract>
        <p>S&#xE9;zary syndrome is a primary cutaneous T-cell lymphoma characterized by
the triad of erythroderma, lymphadenopathy and circulating atypical cells. The
emergence of new molecular targets has enabled the development of drugs such as
alemtuzumab, an anti-CD52 monoclonal antibody, which has shown promising results
in the treatment of this entity. We report the case of a 70-year-old male with
refractory S&#xE9;zary syndrome in whom treatment with alemtuzumab achieved an
80% skin lesion clearance with complete haematologic and radiologic response.
The treatment was discontinued after 4 months due to adverse effects, with the
patient showing a sustained response without disease progression after 13 months
of follow-up.</p>
      </abstract>
      <kwd-group>
        <kwd>Antibodies, monoclonal, humanized</kwd>
        <kwd>Lymphoma, T-Cell, cutaneous</kwd>
        <kwd>S&#xE9;zary syndrome</kwd>
        <kwd>Treatment outcome</kwd>
      </kwd-group>
    </article-meta>
  </front>
  <body>
    <sec sec-type="intro">
      <title>INTRODUCTION</title>
      <p>S&#xE9;zary syndrome (SS) is a rare entity constituting less than 5% of all primary
cutaneous T-cell lymphomas (CTCLs). Its description is a clinical triad composed of
erythroderma, generalized lymphadenopathy, and the presence of S&#xE9;zary cells
in peripheral blood. There is insufficient information to establish a prognostic
index for S&#xE9;zary syndrome, although it is known that the high count of
S&#xE9;zary cells, loss of T-cell markers and chromosomal alterations in
circulating T lymphocytes are independently associated with poor
prognosis.<sup><xref rid="r1" ref-type="bibr">1</xref>,<xref rid="r2" ref-type="bibr">2</xref></sup> It is a difficult-to-treat entity, which often
becomes refractory to chemotherapy agents. We report the case of a patient with SS,
with a favourable and maintained response to alemtuzumab.</p>
    </sec>
    <sec>
      <title>CASE REPORT</title>
      <p>A 70-year-old male, with hypertension and chronic obstructive pulmonary disease, and
no other relevant history, was referred from another centre due to 2 years of
erythroderma with intense pruritus. He was refractory to topical and oral
corticosteroid therapy. On examination, the patient presented a shiny, bright red
erythroderma, slightly indurated to palpation (<xref ref-type="fig" rid="f1">Figure
1</xref>). Bilateral axillary and inguinal lymph nodes were palpable. Analytical
studies showed a basophilia of 14.1% and a slightly elevated LDH (253 IU/l), while
other values were within the normal range. A skin biopsy revealed parakeratosis and
dense lymphocytic infiltrate in the papillary dermis, prone to epidermotropism
(<xref ref-type="fig" rid="f2">Figure 2</xref>). The immunohistochemical
analysis was positive for CD2, CD3, CD4 and CD5; and negative for CD7 and CD8 (<xref ref-type="fig" rid="f3">Figure 3</xref>). The presence of numerous enlarged
lymph nodes in the cervical, axillary and inguinal regions was confirmed by the CT.
The study of peripheral blood showed a S&#xE9;zary cell count of
1031/mm<sup>3</sup>. The axillary lymph node biopsy revealed paracortical
infiltration due to S&#xE9;zary syndrome. The S&#xE9;zary syndrome diagnosis was
performed according to the EORTC criteria. Treatment with PUVA therapy, interferon
alpha, bexarotene and extracorporeal photopheresis was started, sequentially and in
combination, although unsuccessful. The patient exhibited clinical and radiological
signs of disease progression, with enlarged lymph nodes and pruritus, which had
become uncontrollable. New analytical studies have reported 56.8% LUC (large
unstained cell) and 26% basophilia. Adopting a multidisciplinary approach, and after
signing the informed consent, the decision was taken to initiate treatment with
alemtuzumab through off-label use, at doses of 30mg subcutaneously/3 times a week.
Concomitantly, the patient received cotrimoxazole, famciclovir and valganciclovir as
prophylactic treatment. At 3 months of treatment, the patient showed a marked
improvement with 80% erythroderma clearance, pruritus cessation and a decrease in
the S&#xE9;zary cell count to 0. However, the treatment had to be withdrawn 4
months after starting, due to the development of severe neutropenia (leukocytes: 0.3
&#xD7; 10<sup>3</sup>/&#xB5;l; neutrophils: 0.12 &#xD7;
10<sup>3</sup>/&#xB5;l), grade IV heart failure and acute exacerbation of the
underlying disease with bronchospasm, requiring intensive care unit admission. The
patient gradually recovered with supportive treatment and G-CSF therapy. Thirteen
months after medication withdrawal, there were no signs of clinical or
haematological disease activity (<xref ref-type="fig" rid="f1">Figure 1</xref>).</p>
      <p>
        <fig id="f1" orientation="portrait" position="float">
          <label>Figure 1</label>
          <caption>
            <p>Clinical images prior to treatment with alemtuzumab <bold>(a)</bold>; and
13 months after treatment completion, sustaining an almost complete
response <bold>(b)</bold></p>
          </caption>
          <graphic xlink:href="abd-91-05-0642-g01"/>
        </fig>
      </p>
      <p>
        <fig id="f2" orientation="portrait" position="float">
          <label>Figure 2</label>
          <caption>
            <p>Parakeratotic hyperkeratosis and dense lymphocytic infiltrate in the
papillary dermis, with a tendency toward epidermotropism (haematoxylin
and eosin stain, 20x original magnification))</p>
          </caption>
          <graphic xlink:href="abd-91-05-0642-g02"/>
        </fig>
      </p>
      <p>
        <fig id="f3" orientation="portrait" position="float">
          <label>Figure 3</label>
          <caption>
            <p>Skin biopsy immunohistochemical analysis. Positive for CD2, CD3, CD4 and
CD5 (10x original magnification); and negative for CD7 and CD8 (4x
original magnification)</p>
          </caption>
          <graphic xlink:href="abd-91-05-0642-g03"/>
        </fig>
      </p>
    </sec>
    <sec sec-type="discussion">
      <title>DISCUSSION</title>
      <p>SS is a poor prognostic pCTCL, which can be refractory to the multiple regimens used
in over 75% of cases.<sup><xref rid="r3" ref-type="bibr">3</xref></sup> The
emergence of new molecular targets has allowed the use of drugs such as alemtuzumab,
which has provided promising results in Phase 2 clinical trials and observational
studies.<sup><xref rid="r3" ref-type="bibr">3</xref>,<xref rid="r4" ref-type="bibr">4</xref>,<xref rid="r5" ref-type="bibr">5</xref></sup> Alemtuzumab
is a humanized, monoclonal antibody that binds to CD52, a glycosylated peptide
expressed as a surface antigen by B and T lymphocytes (normal and neoplastic),
monocytes, macrophages, NK cells and a granulocytes subset (&lt; 5%), but not by
hematopoietic stem cells.<sup><xref rid="r3" ref-type="bibr">3</xref></sup> It
induces a blood depletion of these cell groups through antibody-dependent
cytotoxicity, complement activation and apoptosis.<sup><xref rid="r2" ref-type="bibr">2</xref>,<xref rid="r4" ref-type="bibr">4</xref></sup> Initially
approved for use in chronic lymphocytic leukaemia, its subsequent approval for
multiple sclerosis has prompted its market withdrawal for hematologic use due to
economic reasons.<sup><xref rid="r6" ref-type="bibr">6</xref></sup> Despite being
classified as an orphan drug by the EMA, this drug can still be used off-label. The
elevated CD52 expression on the CD4<sup>+</sup> T lymphocytes, the main circulating
cell in the SS, has motivated the use of alemtuzumab in mycosis fungoides (MF) and
SS.<sup><xref rid="r3" ref-type="bibr">3</xref>,<xref rid="r7" ref-type="bibr">7</xref></sup> Its efficacy is higher in patients with
erythroderma, intense pruritus and those who have not received prior
treatment<sup><xref rid="r4" ref-type="bibr">4</xref>,<xref rid="r7" ref-type="bibr">7</xref></sup>, with response rates ranging from 70-86% of
cases.<sup><xref rid="r2" ref-type="bibr">2</xref>,<xref rid="r4" ref-type="bibr">4</xref>,<xref rid="r7" ref-type="bibr">7</xref></sup> Masson
<italic>et al.</italic> observed a 70% overall response rate in patients with SS
after a median follow-up of 24 months. This response was sustained for 6 to 56
months in the different series.<sup><xref rid="r5" ref-type="bibr">5</xref>,<xref rid="r7" ref-type="bibr">7</xref></sup> However, the main limitation to the
use of alemtuzumab is its adverse effects, particularly haematological toxicity
(grade 4 cytopenias) and infectious complications (reactivation of CMV,
<italic>Pneumocystis jirovecii</italic> infections and fungal sepsis).<sup><xref rid="r3" ref-type="bibr">3</xref>,<xref rid="r7" ref-type="bibr">7</xref></sup> In addition, post-infusion reactions may occur with fever,
nausea, hypotension, rash/urticaria and fatigue, which are generally limited to the
initial doses of therapy and can be minimized with corticosteroid therapy.<sup><xref rid="r4" ref-type="bibr">4</xref></sup> This high toxicity leads to the
withdrawal of medication in 44% of cases, with a mortality rate of up to 5% that can
be attributed to the drug.<sup><xref rid="r7" ref-type="bibr">7</xref></sup>
Although the standard dose of alemtuzumab is 30mg/3 times a week in most studies,
dosage regimens with lower doses (10mg/3 times a week) revealed similar efficacy
with a decreased risk of infection and haematological toxicity.<sup><xref rid="r8" ref-type="bibr">8</xref></sup> Alemtuzumab has proven to be a
useful alternative in patients with advanced MF and SS; however, its high toxicity
means that its use is reserved for cases of rapidly progressive refractory disease
with lymph node or metastatic involvement.<sup><xref rid="r2" ref-type="bibr">2</xref>,<xref rid="r3" ref-type="bibr">3</xref>,<xref rid="r7" ref-type="bibr">7</xref></sup> Further studies are required to establish the safety
and efficacy of this drug in S&#xE9;zary syndrome, as well as a better
characterization of the patient profile that could most benefit from its use.</p>
    </sec>
  </body>
  <back>
    <fn-group>
      <fn fn-type="COI-statement">
        <p>Conflict of Interest: None</p>
      </fn>
      <fn fn-type="supported-by">
        <p>Financial Support: None</p>
      </fn>
      <fn fn-type="other" id="fn1">
        <label>*</label>
        <p>Work perfomed at the Hospital Universitario Reina Sof&#xED;a &#x2013; C&#xF3;rdoba,
Spain.</p>
      </fn>
    </fn-group>
    <ref-list>
      <title>REFERENCES</title>
      <ref id="r1">
        <label>1</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Jawed</surname>
              <given-names>SI</given-names>
            </name>
            <name>
              <surname>Myskowski</surname>
              <given-names>PL</given-names>
            </name>
            <name>
              <surname>Horwitz</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Moskowitz</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Querfeld</surname>
              <given-names>C</given-names>
            </name>
          </person-group>
          <article-title>Primary cutaneous T-cell lymphoma (mycosis fungoides and
S&#xE9;zary syndrome): part I. Diagnosis: clinical and histopathologic
features and new molecular and biologic markers</article-title>
          <source>J Am Acad Dermatol</source>
          <year>2014</year>
          <volume>70</volume>
          <fpage>205.e1</fpage>
          <lpage>205.e16</lpage>
          <pub-id pub-id-type="pmid">24438969</pub-id>
        </element-citation>
      </ref>
      <ref id="r2">
        <label>2</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Jawed</surname>
              <given-names>SI</given-names>
            </name>
            <name>
              <surname>Myskowski</surname>
              <given-names>PL</given-names>
            </name>
            <name>
              <surname>Horwitz</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Moskowitz</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Querfeld</surname>
              <given-names>C</given-names>
            </name>
          </person-group>
          <article-title>Primary cutaneous T-cell lymphoma (mycosis fungoides and
S&#xE9;zary syndrome): part II. Prognosis, management, and future
directions</article-title>
          <source>J Am Acad Dermatol</source>
          <year>2014</year>
          <volume>70</volume>
          <fpage>223.e1</fpage>
          <lpage>223.e17</lpage>
          <pub-id pub-id-type="pmid">24438970</pub-id>
        </element-citation>
      </ref>
      <ref id="r3">
        <label>3</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Ure</surname>
              <given-names>UB</given-names>
            </name>
            <name>
              <surname>Ar</surname>
              <given-names>MC</given-names>
            </name>
            <name>
              <surname>Salihoglu</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Guner</surname>
              <given-names>SI</given-names>
            </name>
            <name>
              <surname>Baran</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Oguz</surname>
              <given-names>O</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Alemtuzumab in S&#xE9;zary syndrome: efficient but not
innocent</article-title>
          <source>Eur J Dermatol</source>
          <year>2007</year>
          <volume>17</volume>
          <fpage>525</fpage>
          <lpage>529</lpage>
          <pub-id pub-id-type="pmid">17951134</pub-id>
        </element-citation>
      </ref>
      <ref id="r4">
        <label>4</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Lundin</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Hagberg</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Repp</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Cavallin-St&#xE5;hl</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Fred&#xE9;n</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Juliusson</surname>
              <given-names>G</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Phase 2 study of alemtuzumab (anti-CD52 monoclonal antibody) in
patients with advanced mycosis fungoides/Sezary syndrome</article-title>
          <source>Blood</source>
          <year>2003</year>
          <volume>101</volume>
          <fpage>4267</fpage>
          <lpage>4272</lpage>
          <pub-id pub-id-type="pmid">12543862</pub-id>
        </element-citation>
      </ref>
      <ref id="r5">
        <label>5</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Querfeld</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Mehta</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Rosen</surname>
              <given-names>ST</given-names>
            </name>
            <name>
              <surname>Guitart</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Rademaker</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Gerami</surname>
              <given-names>P</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Alemtuzumab for relapsed and refractory erythrodermic cutaneous
T-cell lymphoma: a single institution experience from the Robert H. Lurie
Comprehensive Cancer Center</article-title>
          <source>Leuk Lymphoma</source>
          <year>2009</year>
          <volume>50</volume>
          <fpage>1969</fpage>
          <lpage>1976</lpage>
          <pub-id pub-id-type="pmid">19860617</pub-id>
        </element-citation>
      </ref>
      <ref id="r6">
        <label>6</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Dugas-Breit</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Schulze</surname>
              <given-names>HJ</given-names>
            </name>
            <name>
              <surname>Hallermann</surname>
              <given-names>C</given-names>
            </name>
          </person-group>
          <article-title>New and established treatment options for mycosis fungoides and
S&#xE9;zary syndrome - an update</article-title>
          <source>J Dtsch Dermatol Ges</source>
          <year>2014</year>
          <volume>12</volume>
          <fpage>561</fpage>
          <lpage>569</lpage>
          <pub-id pub-id-type="pmid">24889480</pub-id>
        </element-citation>
      </ref>
      <ref id="r7">
        <label>7</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>de Masson</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Guitera</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Brice</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Moulonguet</surname>
              <given-names>I</given-names>
            </name>
            <name>
              <surname>Mouly</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Bouaziz</surname>
              <given-names>JD</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Longterm efficacy and safety of alemtuzumab in advanced primary
cutaneous T-cell lymphomas</article-title>
          <source>Br J Dermatol</source>
          <year>2014</year>
          <volume>170</volume>
          <fpage>720</fpage>
          <lpage>724</lpage>
          <pub-id pub-id-type="pmid">24438061</pub-id>
        </element-citation>
      </ref>
      <ref id="r8">
        <label>8</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Alinari</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Geskin</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Grady</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Baiocchi</surname>
              <given-names>RA</given-names>
            </name>
            <name>
              <surname>Bechtel</surname>
              <given-names>MA</given-names>
            </name>
            <name>
              <surname>Porcu</surname>
              <given-names>P</given-names>
            </name>
          </person-group>
          <article-title>Subcutaneous alemtuzumab for Sezary Syndrome in the very
elderly</article-title>
          <source>Leuk Res</source>
          <year>2008</year>
          <volume>32</volume>
          <fpage>1299</fpage>
          <lpage>1303</lpage>
          <pub-id pub-id-type="pmid">18096224</pub-id>
        </element-citation>
      </ref>
    </ref-list>
  </back>
</article>
</pmc-articleset>
